Headquartered in Cleveland, OH, Great Lakes Pharmaceuticals assembled a team of experienced and distinguished scientists, clinicians and managers to assure development leading to commercialization of innovative, effective product for prevention of catheter related microbial infections in clinical and in outpatient settings.
Great Lakes Pharmaceuticals obtained funding in the amount of $2 million from Ohio based entities: JumpStart, Case Technology Ventures, and angel fund groups led by North Coast Angel Fund and Ohio Tech Angel Fund. The company also received $2.7 Million NIH SBIR grant designated for financing of clinical trials of B-Lock™ and $244,000 IRS Recovery grant.
In December 2010, Great Lakes Pharmaceuticals secure Series B funding of $3.65 Million led by Charter Life Science Ventures, Early Stage Partners Ventures and MidWest Capital Ventures. Series A investors including Everett Fund, North Coast and Ohio Tech Angel Funds participated in Series B round.
Biofilm-related infections occur in both intensive care (ICU) and non-ICU settings such as hemodialysis stations, oncology wards, pediatric patients and patients needing total parenteral nutrition. The estimated infection rates in all those setting is about 5270,000 cases/year of catheter-associated sepsis.
Biofilms are responsible for significant attributable mortality (12-25%) and morbidity, extremely difficult to treat (due to resistance development) and expensive to manage (costing $4.6 billion/year).
Addressing an Unmet Need
Currently there are no antibiofilm products on the market for treatment and prevention, in particular in the prevention of intra-luminal infections.
Great Lakes Pharmaceuticals is preparing testing of its first antibiofilm products effective in prevention of catheter-associated infections in clinical studies in the US and selected EU countries.